Regeneron Pharmaceuticals, Inc. (REGN) announced the European Commission has approved Ordspono or odronextamab to treat adult patients with relapsed or refractory follicular lymphoma or R/R diffuse large B-cell lymphoma, after two or more lines of systemic therapy. This marks the first regulatory approval of Ordspono. Ordspono is a bispecific antibody that acts by linking the lymphoma cell to a killer T cell.
The company said the approval is based on results from the Phase 1 ELM-1 and pivotal Phase 2 ELM-2 trials, which demonstrated robust, durable response rates in adults with R/R FL or R/R DLBCL.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.